CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 100 enrolled
Drug / intervention
fosaprepitantdrug
Likely dose
fosaprepitant 150mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04636632
NCT04636632Phase 1Completed
CompareCT.gov

Weekly Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma: a Prospective Pilot Study

Sun Yat-sen University·interventional·Posted Nov 19, 2020·Updated Nov 7, 2022

In Brief

A Phase 1 clinical trial evaluating fosaprepitant for Nasopharyngeal Carcinoma. Completed, enrolled 100 participants across 1 site.

Detailed Summary

This is an opene-label, single center, randomized prospective pilot study to compare the efficacy of weekly versus triweekly fosaprepitant regimens for the prevention of nausea and emesis during concurrent chemoradiotherapy for nasopharyngeal carcinoma (NPC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedNov 19, 2020
Enrollment StartNov 24, 2020
Primary CompletionNov 4, 2022
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 5.6 years ago

Interventions

fosaprepitantdrug

fosaprepitant 150mg/m2 weekly or triweekly during concurrent chemoradiotherapy